Cardiovascular manifestations of rheumatologic diseases

Circulation

Volumn 116, Issue 20, 2007, Pages 2346-2355

  Roman, Mary J ^a,b   Salmon, Jane E ^a  

^a Department of Obstetrics Gynecology   (United States)

^b Division of Cardiology   (United States)

Author keywords

Arthritis, psoriatic; Rheumatoid arthritis; Spondylitis, ankylosing; Systemic lupus erythematosus; Systemic sclerosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTINUCLEAR ANTIBODY; ATORVASTATIN; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; NICARDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RHEUMATOID FACTOR; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY;

ANKYLOSING SPONDYLITIS; ANTIBIOTIC PROPHYLAXIS; AORTA DISEASE; ARTERITIS; ARTHRITIS; ARTHROPATHY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CORONARY ARTERY; HEART FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; KIDNEY DISEASE; MORNING STIFFNESS; MOUTH ULCER; MYOCARDIAL DISEASE; NEUROLOGIC DISEASE; OSTEOPENIA; PERICARDIAL DISEASE; PERICARDIAL EFFUSION; PERICARDITIS; PHOTOSENSITIVITY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RADIOGRAPHY; RASH; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; SYNDROME CREST; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VALVULAR HEART DISEASE; VASCULAR DISEASE; VASCULITIS;

CARDIOVASCULAR DISEASES; HUMANS; PREVALENCE; RHEUMATIC DISEASES; RISK FACTORS;

EID: 36048954793     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.678334     Document Type: Article

References (131)

1. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41:778-799.
2. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
3. Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis. 2003;62:870-874.
4. Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J, Rönnelid J, Harris HE, Ulfgren A-K, Rantapää-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L, and the Epidemiological Investigation of Rheumatoid Arthritis Study Group. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54:38-46.
5. Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907-916.
6. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, Spitz PW, Haga M, Kleinheksel SM, Cathey MA. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37:481-494.
7. Wållberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol. 1997;24:445-451.
8. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107:1303-1307.
9. Myllykangas-Luosujarvi R, Aho K, Kautianen H, Isomaki H. Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol. 1995;22:1065-1067.
10. Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol. 2004;93:198-200.
11. Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis. 2004;63:952-955.
12. del Rincón I, Williams K, Stern MP, Freeman Gl, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44:2737-2745.
13. Maradit-Kremer H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen, Gabriel SE. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005;52:402-411.
14. Hansson G. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
15. Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD, Sammaritano L, Devereux RB, Schwartz JE, Levine DM, Salmon JE. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis: prevalence and associated factors. Ann Intern Med. 2006;144:249-256.
16. Gonzalez-Juanatey C, Llorca J, Testa A, Revuelta J, Garcia-Porrua C, Gonzalez-Gay MA. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine. 2003;82:407-413.
17. Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sooka T, Pincus T, Avalos I, Stein CM. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum. 2005;52:3045-3053.
18. Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Seidinger D, Weigel G, Schwaringer I, Wolozcszuk W, Steiner G, Smolen JS. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation. 2005;111:204-211.
19. Krishnan E, Lingala VB, Singh G. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation. 2004;110:1774-1779.
20. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359:1173-1177.
21. Jacobsson LTH, Turesson C, Gh lfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005;32:1213-1218.
22. Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, Bathon JM. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum. 2006;55:333-337.
23. Hansen TW, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation. 2006;113:664-670.
24. Mattace-Raso FUS, van der Cammen TJM, Hofman A, van Popele NM, Bos ML, Schalekamp MADH, Asmar A, Reneman RS, Hoeks APG, Breteler MMB, Witteman JCM. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation. 2006;113:657-663.
25. Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol. 2004;24:969-974.
26. Wong M, Toh L, Wilson A, Rowley K, Karschimkus C, Prior D, Romas E, Clemens L, Dragicevic G, Harianto H, Wicks I, McColl G, Best J, Jenkins A. Reduced arterial elasticity in rheumatoid arthritis and the relation to vascular disease risk factors and inflammation. Arthritis Rheum. 2003;48:81-89.
27. Klocke R, Cockcroft JR, Taylor GJ, Hall IR, Blake DR. Arterial stiffness and central blood pressure, as determined by pulse wave analysis, in rheumatoid arthritis. Ann Rheum Dis. 2003;62:414-418.
28. Roman MJ, Devereux RB, Schwartz JE, Lockshin MD, Paget SA, Davis A, Crow MK, Sammaritano L, Levine DM, Shankar B-A, Moeller E, Salmon JE. Arterial stiffness in chronic inflammatory diseases. Hypertension. 2005;46:194-199.
29. Mäki-Petäjä KM, Hall FC, Booth AD, Wallace SML, Yasmin, Bearcroft PWP, Harish S, Furlong A, McEnierny CM, Brown J, Wilkinson IB. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-α therapy. Circulation. 2006;114:1185-1192.
30. van Doornum S, McColl G, Wicks IP. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis. 2004;63:1571-1575.
31. Cruikshank B. Heart lesions in rheumatoid disease. J Path Bact. 1958;76:223-240.
32. Morris PB, Imber MJ, Heinsimer JA, Hlatky MA, Reimer KA. Rheumatoid arthritis and coronary arteritis. Am J Med. 1986;57:689-690.
33. Watts RA, Mooney J, Lane SE, Scott DGI. Rheumatoid vasculitis: becoming extinct? Rheumatology. 2004;43:920-923.
34. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med. 2004;116:305-311.
35. Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, Gabriel SE. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52:412-420.
36. Crowson CS, Nicola PJ, Maraddit Kremers H, O'Fallon WM, Therneau TM, Jacobsen SJ, Roger VL, Ballman KV, Gabriel SE. How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? Arthritis Rheum. 2005;52:3039-3044.
37. Bhatia GS, Sosin MD, Patel JV, Grindulis KA, Khattak FH, Hughes EA, Lip GYH, Davis RC. Left ventricular systolic dysfunction in rheumatoid disease: an unrecognized burden? J Am Coll Cardiol. 2006;4:1169-1174.
38. Corrao S, Sallì L, Arnone S, Scaglione R, Pinto A, Licata G. Echo-Doppler left ventricular filling abnormalities in patients with rheumatoid arthritis without clinically evident cardiovascular disease. Eur J Clin Invest. 1996;26:293-297.
39. Montecucco C, Gobbi G, Perlini S, Rossi S, Grandi AM, Caporali R, Finardi G. Impaired diastolic function in active rheumatoid arthritis: relationship with disease duration. Clin Exp Rheumatol. 1999;17:407-412.
40. Di Franco M, Paradiso M, Mammarella A, Paoletti V, Labbadia G, Coppotelli L, Taccari E, Musca A. Diastolic function abnormalities in rheumatoid arthritis: evaluation by echo Doppler transmitral flow and pulmonary venous flow: relation with duration of disease. Ann Rheum Dis. 2000;59:227-229.
41. Gonzalez-Juanatey C, Testa A, Garcia-Castelo, Garcia-Porrua C, Llorca J, Ollier WER, Gonzalez-Gay MA. Echocardiographic and Doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum. 2004;33:231-238.
42. Mody GM, Stevens JE, Meyers OL. The heart in rheumatoid arthritis: a clinical and echocardiographic study. Q J Med. 1987;65:921-928.
43. Guedes C, Bianchi-Fior P, Cormier B, Barthelemy B, Rat A-C, Boissier M-C. Cardiac manifestations of rheumatoid arthritis: a case-control transesophageal study in 30 patients. Arthritis Care Res. 2001;45:129-135.
44. Cathcart ES, Spodick DH. Rheumatoid heart disease: a study of the incidence and nature of cardiac lesions in rheumatoid arthritis. N Engl J Med. 1962;266:959-964.
45. Hara KS, Ballard DJ, Ilstrup DM, Connolly DC, Vollertsen RS. Rheumatoid pericarditis: clinical features and survival. Medicine. 1990;69:81-91.
46. Nomeir A-M, Turner R, Watts E, Smith D, West G, Edmonds J. Cardiac involvement in rheumatoid arthritis. Ann Intern Med. 1973;79:800-806.
47. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-1277.
48. Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy: a study of 36 necropsy patients. Am J Med. 1975;58:243-264.
49. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of SLE. Am J Med. 1976;60:221-225.
50. Björnådal L, Yin L, Granath F, Klareskog L, Ekbom A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol. 2004;31:713-719.
51. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, D'Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145:408-415.
52. Petri M, Perz-Gutthan S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992;93:513-519.
53. Manzi S, Selzer F, Sutton-Tyrrell, Fitzgerald SG, Rairie J, Tracy RP, Kuller LH. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 1999;42:51-60.
54. Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Pratt JE, Tracy RP, Kuller LH, Manzi S. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum. 2004;50:151-159.
55. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Côté R, Grover SA, Fortin PR, Clarke AE, Senécal J-L. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331-2337.
56. de Leeuw K, Freire B, Smit AJ, Bootsma H, Kallenberg CG, Bijl M. Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus. 2006;15:675-682.
57. Svenungsson E, Jensen-Urstad K, Heimbηrger M, Silveira A, Hmasten A, de Faire U, Witztum JL, Frostegård J. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation. 2001;104:1887-1893.
58. Roman MJ, Shanker B-A, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2399-2406.
59. Azanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, Stein CM. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2407-2415.
60. Farzaneh-Far A, Roman MJ, Lockshin MD, Devereux RB, Paget SA, Crow MK, Davis A, Sammaritano L, Levine DM, Salmon JE. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum. 2006;54:3918-3925.
61. Von Feldt JM, Scalzi LV, Cucchiara AJ, Morthala S, Kealey C, Flagg SD, Genin A, Van Dyke AL, Nackos E, Chander A, Gehrie E, Cron RQ, Whitehead AS. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54:2220-2227.
62. Roman MJ, Crow MK, Lockshin MD, Devereux RB, Paget SA, Sammaritano L, Levine DM, Davis A, Salmon JE. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2007;56:3412-3419.
63. Selzer F, Sutton-Tyrrell K, Fitzgerald S, Tracy R, Kuller L, Manzi S. Vascular stiffness in women with systemic lupus erythematosus. Hypertension. 2001;37:1075-1082.
64. Crozier IG, Li E, Milne MJ, Nicholls GM. Cardiac involvement in systemic lupus erythematosus detected by echocardiography. Am J Cardiol. 1990;65:1145-1148.
65. Cervera R, Font J, Pare C, Azqueta M, Perez-Villa F, Lopez-Soto A, Ingelmo M. Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients. Ann Rheum Dis. 1992;51:156-159.
66. Omdal R, Lunde P, Rasmussen K, Mellgren SI, Husby G. Transesophageal and transthoracic echocardiography and Doppler-examinations in systemic lupus erythematosus. Scand J Rheumatol. 2001;30:275-281.
67. Leung WH, Wong KL, Lau CP, Wong CK, Liu HW. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med. 1990;89:411-419.
68. Pieretti J, Roman MJ, Devereux RB, Lockshin MD, Crow MK, Paget SA, Sammaritano L, Levine DM, Salmon JE. Systemic lupus erythematosus predicts increased left ventricular mass independent of traditional stimuli to hypertrophy. Circulation. 2007;116:419-426.
69. Borenstein DG, Fye WB, Arnett FC, Stevens MB. The myocarditis of systemic lupus erythematosus: association with myositis. Ann Intern Med. 1978;89:619-624.
70. Law WG, Thong BY, Lian TY, Kong KO, Chng HH. Acute lupus myocarditis: clinical features and outcome of an oriental case series. Lupus. 2005;14:827-831.
71. Libman E, Sachs B. A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med. 1924;33:701-737.
72. Klinkhoff AV, Thompson CR, Reid GD, Tomlinson CW. M-mode and two-dimensional echocardiographic abnormalities in systemic lupus erythematosus. JAMA. 1985;253:3273-3277.
73. Straaton KV, Chatham WW, Reveille JD, Koopman WJ, Smith SH. Clinically significant valvular heart disease in systemic lupus erythematosus. Am J Med. 1988;85:645-650.
74. Roldan CA, Shively BK, Crawford MH. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med. 1996;335:1424-1430.
75. Galve E, Candell-Riera J, Pigrau C, Permanyer-Miralda G, Garcia-Del-Castillo H, Soler-Soler J. Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus. N Engl J Med. 1988;319:817-823.
76. Sturfelt G, Eskilsson J, Nived O, Truedsson L, Valind S. Cardiovascular disease in systemic lupus erythematosus: a study of 75 patients from a defined population. Medicine. 1992;71:216-223.
77. Perez-Villa F, Font J, Azqueta M, Espinosa G, Pare C, Cervera R, Reverter JC, Ingelmo M, Sanz G. Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, follow-up study. Arthritis Rheum. 2005;53:460-467.
78. Roldan CA, Shively BK, Crawford MH. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med. 1996;335:1424-1430.
79. Nihoyannopoulos P, Gomez PM, Joshi J, Loizou S, Walport MJ, Oakley CM. Cardiac abnormalities in systemic lupus erythematosus: association with raised anticardiolipin antibodies. Circulation. 1990;82:369-375.
80. Khamasta MA, Cervera R, Asherson RA, Font J, Gil A, Coltart DJ, Vazquez JJ, Paré C, Ingelmo M, Oliver J, Hughes GRV. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet. 1990;335:1541-1544.
81. Roldan CA, Gelgand EA, Qualls CR, Sibbitt WL Jr. Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am J Cardiol. 2005;95:1441-1447.
82. Doherty NE III, Feldman G, Maurer G, Siegel RJ. Echocardiographic findings in systemic lupus erythematosus. Am J Cardiol. 1988;61:1142-1143.
83. Reveille JD. Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations. Curr Rheumatol Reports. 2003;5:160-167.
84. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581-590.
85. Ioannidis JPA, Vlachoyiannopoulos PG, Haidich A-B, Medsger TA Jr, Lucas M, Michet CJ, Kuwana M, Yasuoka H, van den Hoogen F, te Boome L, van Laar JM, Verbeet NL, Matucci-Cerinic M, Georgountzos A, Moutsopoulos HM. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med. 2005;118:2-10.
86. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Avvedimento EV, Gabrielli A. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006;354:2667-2676.
87. Bulkley BH, Ridolfi RL, Salyer WR, Hutchins GM. Myocardial lesions of progressive systemic sclerosis: a cause of cardiac dysfunction. Circulation. 1976;53:483-490.
88. Follansbee WP, Curtiss EI, Medsger TA, Steen VD, Uretsky BF, Owens GR, Rodnan GP. Physiologic abnormalities of cardiac function in progressive systemic sclerosis. N Engl J Med. 1984;310:142-148.
89. Kahan A, Devaux JY, Amor B, Menkès CJ, Weber S, Nitenberg A, Venot A, Guérin F, Degeorges M, Roucayrol JC. Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. N Engl J Med. 1986;314:1397-1402.
90. Vacca A, Siotto P, Cauli A, Montisci R, Garau P, Ibba V, Mameli A, Passiu G, Iliceto S, Mathieu A. Absence of epicardial coronary stenosis in patients with systemic sclerosis and severe impairment of coronary flow reserve. Ann Rheum Dis. 2006;65:274-275.
91. Akram MR, Handler CE, Williams M, Carulli MT, Andron M, Black CM, Denton CP, Coghlan JG. Angiographically proven coronary artery disease in scleroderma. Rheumatology. 2006;45:1395-1398.
92. Vignaux O, Allanore Y, Meune C, Pascal O, Duboc D, Weber S, Legmann P, Kahan A. Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann Rheum Dis. 2005;64:1268-1273.
93. Alexander EL, Firestein GS, Weiss JL Heuser RR, Leitl G, Wagner HN Jr, Brinker JA, Ciuffo AA, Becker LC. Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. Ann Intern Med. 1986;105:661-668.
94. Del Papa N, Colombo G, Fracchiolla N, Moronetti LM, Ingegnoli F, Maglione W, Comina DP, Vitale C, Fantini F, Cortelezzi A. Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum. 2004;50:1296-1304.
95. Meune C, Allanore Y, Devaux J-Y, Dessault O, Duboc D, Weber S, Kahan A. High prevalence of right ventricular systolic dysfunction in early systemic sclerosis. J Rheumatol. 2004;31:1941-1945.
96. Hsaio S-H, Lee C-Y, Chang S-M, Lin S-K, Liu C-P. Right heart function in scleroderma: insights from myocardial Doppler tissue imaging. J Am Soc Echocardiogr. 2006;19:507-514.
97. Cheng K-S, Tiwari A, Boutin A, Denton CP, Black CM, Morris R, Hamilton G, Seifalian AM. Carotid and femoral arterial wall mechanics in scleroderma. Rheumatology. 2003;42:1299-1305.
98. Moyssakis I, Gialafos E, Vassiliou V, Taktikou E, Katsiari C, Papadopoulos DP, Sfikakis PP. Aortic stiffness in systemic sclerosis in increased independently of the extent of skin involvement. Rheumatology. 2005;44:251-254.
99. Roberts NK, Cabeen WR Jr, Moss J, Clements PJ, Furst DE. The prevalence of conduction defects and cardiac arrhythmias in progressive systemic sclerosis. Ann Intern Med. 1981;94:38-40.
100. Kostis JB, Seibold JR, Turkevich D, Masi AT, Grau RG, Medsger TA Jr, Steen VD, Clements PJ, Szydlo L, D'Angelo WA. Prognostic importance of cardiac arrhythmias in systemic sclerosis. Am J Med. 1988;84:1007-1015.
101. Ferri C, Bernini L, Bongiorni MG, Levorato D, Viegi G, Bravi P, Contini C, Pasero G, Bombardieri S. Noninvasive evaluation of cardiac dysrhythmias, and their relationship with multisystemic symptoms, in progressive systemic sclerosis patients. Arthritis Rheum. 1985;28:1259-1266.
102. Rokas S, Mavrikakis M, Agrios N, Mylonas D, Antoniadou L, Moulopoulos S. Electrophysiologic abnormalities of cardiac function in progressive systemic sclerosis. J Electrocardiol. 1996;29:17-25.
103. Byers RJ, Marshall DAS, Freemont AJ. Pericardial involvement in systemic sclerosis. Ann Rheum Dis. 1997;56:393-394.
104. Maione S, Cuomo G, Giunta A, de Horatio LT, La Montagna G, Manguso F, Alagia I, Valentini G. Echocardiographic alterations in systemic sclerosis: a longitudinal study. Sem Arthritis Rheum. 2005;34:721-727.
105. Carter ET, McKenna CH, Brian DD, Kurland LT. Epidemiology of ankylosing spondylitis in Rochester, Minnesota, 1935-73. Arthritis Rheum. 1979;22:365-370.
106. Rigby AS. Ankylosing spondylitis. Br J Rheumatol. 1991;30:50-53.
107. van der Linden SM, Valkenburg HA, De Jongh, Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals: a comparison of relatives of spondylitis patients with the general population. Arthritis Rheum. 1984;27:241-249.
108. Bulkley BH, Roberts WC. Ankylosing spondylitis and aortic regurgitation: description of the characteristic cardiovascular lesion from study of eight necropsy patients. Circulation. 1973;58:1014-1027.
109. Kinsella TD, Johnson LG, Sutherland RI. Cardiovascular manifestations of ankylosing spondylitis. Can Med Assoc J. 1974;111:1309-1311.
110. O'Neill TW, King G, Graham IM, Molony J, Bresnihan B. Echocardiographic abnormalities in ankylosing spondylitis. Ann Rheum Dis 12:51:652-654.
111. Yildirir A, Aksoyek S, Calguneri M, Oto A, Kes S. Echocardiographic evidence of cardiac involvement in ankylosing spondylitis. Clin Rheumatol. 2002;21:129-143.
112. Brunner F, Kunz A, Weber U, Kissling R. Ankylosing spondylitis and heart abnormalities: do cardiac conduction disorders, valve regurgitation and diastolic dysfunction occur more often in male patients with diagnosed ankylosing spondylitis for over 15 years than in the normal population? Clin Rheumatol. 2005;25:24-29.
113. Sukenik S, Pras A, Buskila D, Katz A, Snir Y, Horowitz J. Cardiovascular manifestations of ankylosing spondylitis. Clin Rheumatol. 1987;6:588-592.
114. Arnason JA, Patel AK, Rahko PS, Sundstrom WR. Transthoracic and transesophageal echocardiographic evaluation of the aortic root and subvalvular structures in ankylosing spondylitis. J Rheumatol. 1996;23:120-123.
115. Roldan CA, Chavez J, Wiest PW, Qualls CR, Crawford MH. Aortic root disease and valve disease associated with ankylosing spondylitis. J Am Coll Cardiol. 1998;32:1397-1404.
116. Thomas D, Hill W, Geddes R, Sheppard M, Arnold J, Fritzsche J, Brooks PM. Early detection of aortic dilatation in ankylosing spondylitis using echocardiography. Aust NZ J Med. 1982;12:10-13.
117. Tucker CR, Fowles RE, Calin A, Popp RL. Aortitis in ankylosing spondylitis: early detection of aortic root abnormalities with two dimensional echocardiography. Am J Cardiol. 1982;49:680-686.
118. LaBresh KA, Lally EV, Sharma SC, Ho G Jr. Two-dimensional echocardiographic detection of preclinical aortic root abnormalities in rheumatoid variant diseases. Am J Med. 1985;78:908-912.
119. Bergfeldt L, Möller E. Complete heart block: another HLA B27 associated disease manifestation. Tissue Antigens. 1983;21:385-390.
120. Peeters AJ, ten Wolde S, Sedney MI, de Vries RR, Dijkmans BA. Heart conduction disturbance: an HLA-B27 associated disease. Ann Rheum Dis. 1991;50:348-350.
121. Crowley JJ, Donnelly SM, Tobin M, FitzGerald O, Bresnihan B, Maurer BJ, Quigley PJ. Doppler echocardiographic evidence of left ventricular diastolic dysfunction in ankylosing spondylitis. Am J Cardiol. 1993;71:1337-1340.
122. Caliskan M, Erdogan D, Gullu H, Yilmaz S, Gursoy Y, Yildirir A, Yucel E, Muderrisoglu H. Impaired coronary microvascular and left ventricular diastolic functions in patients with ankylosing spondylitis. Atherosclerosis. December 12, 2006. DOI: 10.1016/j.atherosclerosis.2006.11.003. Available at: http://www.atherosclerosis-journal.com/article/PIIS0021915006006733/fulltext. Accessed October 25, 2007.
123. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis. 1993;52:174-176.
124. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33:2167-2172.
125. Sari I, Okan T, Akar S, Cece H, Altay C, Secil M, Birlik M, Onen F, Akkoc N. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology. 2006;45:283-286.
126. Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol. 2000;27:1247-1250.
127. Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, Stern RS, Feldman SR, Rolstad T. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53:573-577.
128. Madland TM, Apalset EM, Johannessen AE, Rossebo B, Brun JG. Prevalence, disease manifestations, and treatment of psoriatic arthritis in Western Norway. J Rheumatol. 2005;32:1918-1922.
129. Gonzalez-Juanatey C, Amigo-Diaz E, Miranda-Filloy JA, Testa A, Revuelta J, Garcia-Porrua C, Martin J, Llorca J, Gonzalez-Gay MA. Lack of echocardiographic and Doppler abnormalities in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerotic risk factors. Sem Arthritis Rheum. 2006;35:333-339.
130. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic, I: causes and risk of death. Arthritis Rheum. 1997;40:1868-1872.
131. Gelfand JM, Meimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735-1741.